Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Breast cancer (BC) is highly heterogeneous, with significant unmet needs for HER-2 negative subtypes like triple-negative or endocrine-resistant BC.
• Current treatments are limited for these BC subtypes due to a lack of specific molecular targets.
• Antibody drug conjugates (ADCs) represent a promising targeted therapy class, selectively delivering cytotoxic agents to cancer cells.

Purpose of the Study:

• To review the current role and potential of Antibody drug conjugates (ADCs) in treating HER-2 negative breast cancer.
• To explore novel therapeutic strategies involving ADCs for difficult-to-treat BC subtypes.
• To discuss emerging ADC subclasses and combination therapies.

Main Methods:

• Literature review of current research on Antibody drug conjugates (ADCs) in breast cancer.
• Analysis of clinical trial data for ADC efficacy in HER-2 negative BC.
• Exploration of future directions, including new molecular targets and ADC variations.

Main Results:

• ADCs demonstrate potential for targeted delivery of cytotoxic agents, reducing side effects.
• Ongoing clinical trials show promise for ADCs in various BC subtypes, including HER-2 negative cases.
• Novel targets and ADC subclasses are being investigated to expand therapeutic options.

Conclusions:

• ADCs are a rapidly advancing therapeutic modality for breast cancer, particularly for HER-2 negative subtypes.
• Future research should focus on identifying new molecular targets and exploring ADC combination therapies.
• Emerging ADC subclasses, such as bicycle drug conjugates and bispecific ADCs, hold significant promise for improved BC treatment outcomes.